Sumitomo Mitsui DS Asset Management Company Ltd Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui DS Asset Management Company Ltd cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the third quarter, Holdings Channel.com reports. The firm owned 11,581 shares of the biopharmaceutical company’s stock after selling 533 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,185,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its stake in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $26,000. Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $30,000. Meeder Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 1,237.5% in the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 297 shares during the period. Finally, Itau Unibanco Holding S.A. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $79,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,398 shares of company stock valued at $13,595,460 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.3 %

Alnylam Pharmaceuticals stock opened at $295.93 on Monday. The company’s 50 day moving average is $271.82 and its two-hundred day moving average is $217.05. The firm has a market cap of $37.43 billion, a PE ratio of -110.42 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The firm’s revenue was up 107.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.21) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. UBS Group upped their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. Raymond James lifted their target price on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $286.82.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.